|
Title
|
|
|
|
Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| First-line bevacizumab-based therapies have been shown to improve clinical outcomes in patients with non-squamous non-small-cell lung cancer (NSCLC). We aimed to descriptively analyse patients with non-squamous NSCLC who received a long-term period of maintenance bevacizumab. This retrospective study included 104 patients who had already reached a progression-free survival (PFS) of at least 9 months. Median overall survival and PFS were 30.7 and 15.1 months, respectively. The overall response rate was 83 %. Weight loss ae5 %, ECOG PS = 0, or low number of metastatic sites seem to be predictive factors of good evolution. The incidence of bevacizumab-related adverse events appeared to be similar as the previous studies. Our findings show that there is a long-term survivor group whom the administration of bevacizumab resulted in a relevant prolongation of response without new safety signals. Due to the population heterogeneity, it was not possible to identify the standardised predictive factors. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Clinical and translational oncology
| |
|
Publication
|
|
|
|
2017
| |
|
ISSN
|
|
|
|
1699-048X
| |
|
DOI
|
|
|
|
10.1007/S12094-016-1527-8
| |
|
Volume/pages
|
|
|
|
19
:2
(2017)
, p. 219-226
| |
|
ISI
|
|
|
|
000392315900010
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|
Full text (publisher's version - intranet only)
|
|
|
|
| |
|